EQUULUS In the media

---

Congratulations to Dr. Kevin Murnane, Associate Professor of Pharmacology, Toxicology, and Neuroscience and Director of Basic Science Research for the Louisiana Addiction Research Center at LSU Health Shreveport for being part of the cross-disciplinary team awarded a $2.4 million grant by the NIH to explore the potential of #psychedelics in treating #methamphetamine use disorder. Kevin is also, Co-Founder and Neuropharmacology & Neurotoxicology Director at EQUULUS Therapeutics! 

Newsweek

Mental health disorders have long been a significant global challenge, affecting millions of individuals and placing an immense burden on healthcare systems worldwide. Despite substantial investments in research and development, many CNS disorders remain inadequately treated, highlighting the need for innovative approaches to mental health treatment. In recent years, several companies have emerged, dedicating their efforts to developing groundbreaking therapies that could revolutionize the field of mental health.

Clinical Leader

As compared to other industries I’ve worked in, the clinical research folks are among the most willing, enthusiastic even, to share what they know. Every call and Zoom meeting I’ve had with professionals in the field has gone quite well. No one’s spilling their guts exactly, but everyone is happy to impart words of wisdom from their own little industry niche. Now that I think about it, it does seem a bit at odds with the way the pharmaceutical industry works — you know, holding some things close to the vest and wanting to be first to market and all.

Microdose

Navigating the complex landscape of pharmaceutical development for central nervous system (CNS) disorders is no small feat. Current treatments vary widely, from antipsychotics to antidepressants and mood stabilizers. However, for EQUULUS, a burgeoning neuroscience biotech company focused on transforming the treatment landscape freshly out of stealth mode, the quest involves a radical pivot towards utilizing a non-hallucinogenic analog of ibogaine, which represents a bold, yet promising venture into CNS therapeutics.

Psychedelic Alpha

EQUULUS Therapeutics is the latest psychedelicdrug developer to emerge from stealth after a quieter spell on the company formation front. It’shelmed by Robert Discordia, who was most recently chief scientific officer at private psychedelicdrug developer CaaMTech.

LaBiotech

Small-molecule drugs have been a mainstay of the pharmaceutical industry for nearly a century and they continue to play a crucial role in the industry’s therapeutic arsenal. Advances in technology and biopharmaceutical research in the last 10 years or so have provided companies with the ability to discover and develop more and more innovative small-molecule therapeutics that hold the ability to treat a range of different indications. 

Drug Discovery Online

Developing new therapies for central nervous system (CNS) disorders, which are currently treated by a multitude of therapies ranging from antipsychotics to antidepressants to mood stabilizers and more, can be a challenging endeavor for most any pharma. But if you’re a startup just coming out of stealth mode andseeking a program rooted in hallucinogenics, that journey just got a little tougher — but all the more worthwhile.